Figure 2.
Kaplan–Meier curves for overall survival in patients treated with dabrafenib and trametinib (n=60). Median OS and 3 years OS rate were 17.6 (95% CI, 13.1–22.1) month and 28.8% (95% CI, 19.1-43.6%), respectively.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.